Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

AIMS: This pre‐specified analysis of the DELIVER trial examined whether clinical benefits of dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF) >40% varied by baseline New York Heart Association (NYHA) class and examined the treatment effects on NYHA class over tim...

Descripción completa

Detalles Bibliográficos
Autores principales: Ostrominski, John W., Vaduganathan, Muthiah, Claggett, Brian L., de Boer, Rudolf A., Desai, Akshay S., Dobreanu, Dan, Hernandez, Adrian F., Inzucchi, Silvio E., Jhund, Pardeep S., Kosiborod, Mikhail, Lam, Carolyn S.P., Langkilde, Anna M., Lindholm, Daniel, Martinez, Felipe A., O'Meara, Eileen, Petersson, Magnus, Shah, Sanjiv J., Thierer, Jorge, McMurray, John J.V., Solomon, Scott D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Focused Issue on Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804680/
https://www.ncbi.nlm.nih.gov/pubmed/36054231
http://dx.doi.org/10.1002/ejhf.2652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804680/
https://www.ncbi.nlm.nih.gov/pubmed/36054231
http://dx.doi.org/10.1002/ejhf.2652

Ejemplares similares